AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ABBV?
Source: Fool
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 206.110
Low
223.00
Averages
252.00
High
289.00
Current: 206.110
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Apple, Amazon, and TSMC Deliver Earnings Triple Plays
- Earnings Highlights: Apple, Amazon, and TSMC have all achieved a 'triple play' this quarter, delivering growth in earnings, revenue, and guidance, which underscores strong market demand and business resilience, further solidifying their leadership positions in their respective industries.
- Market Reaction: Investors reacted positively to the earnings reports from these three companies, driving stock prices higher, which reflects a renewed confidence in tech stocks and may attract more capital inflows into the technology sector.
- Industry Impact: The robust performance of these companies not only enhances their market valuations but may also lead to upward revisions in earnings expectations for other tech firms, creating a virtuous cycle that could further drive the recovery of the entire industry.
- Future Outlook: As the global economy gradually recovers, the success stories of Apple, Amazon, and TSMC may inspire other companies to adopt similar growth strategies, fostering innovation and investment that drive long-term growth.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
